

glomerulus and interstitium, resulting in T cell-mediated kidney inflammation in SLE patients. Identifying antigen(s) that are recognized by T cells is also important in elucidating the molecular pathomechanisms of LN. Analysis of the cytokine profile in the present study showed the predominance of Th2-type T cells. These findings suggest two distinct strategies for therapy. The cytokine shift from Th2 to Th1 may be desirable to repair glomerulonephritis in patients with SLE, if Th2-type T cells function as pathogenic T cells, and modification from Th1 to Th2 may be hopeful for therapy in the case of regulatory Th2-type T cells. Establishment of T cells infiltrating into kidneys should shed light on the function of Th2-type T cells and selection of Th1/Th2 therapy in LN.

#### ACKNOWLEDGMENTS

We thank Ms Eriko Onose and Ms Yuriko Nagai for the excellent technical assistance. We also thank Dr. F. G. Issa for the critical reading of the manuscript and Ms Noriko Takanashi and Ms Rieko Nohda for secretarial assistance.

#### REFERENCES

- Appel GB, Silva FG, Pirani CL, Meltzer JI, Estes D. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. *Medicine (Baltimore)* 1978;57:371-410.
- Datta SK, Patel H, Berry D. Induction of a cationic shift in IgG anti-DNA autoantibodies: role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. *J Exp Med* 1987;165:1252-68.
- Shivakumar S, Tsokos GC, Datta SK. T cell receptor  $\alpha/\beta$  expressing double-negative (CD4<sup>-</sup>/CD8<sup>-</sup>) and CD4<sup>+</sup> T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. *J Immunol* 1989;143:103-12.
- Suzuki N, Harada T, Mizushima Y, Sakane T. Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. *J Immunol* 1993;151:1128-36.
- Rajagopalan S, Zordan T, Tsokos GC, Datta SK. Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4<sup>+</sup>-8<sup>-</sup> T helper cell lines that express the  $\gamma\delta$  T-cell antigen receptor. *Proc Natl Acad Sci U S A* 1990;87:7020-4.
- Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. *J Clin Invest* 1995;95:531-41.
- Sumida T, Yonaha F, Maeda T, Tanabe E, Koike T, Tomioka H, et al. T cell receptor repertoire of infiltrating T cells in lips of Sjogren's syndrome patients. *J Clin Invest* 1992;89:681-5.
- Yonaha F, Sumida T, Maeda T, Tomioka H, Koike T, Yoshida S. Restricted junctional usage of T cell receptor V $\beta$ 2 and V $\beta$ 13 genes, which are overrepresented on infiltrating T cells in the lips of patients with Sjogren's syndrome. *Arthritis Rheum* 1992;35:1362-7.
- Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. *Scand J Rheumatol* 1998;27:219-24.
- Viallard JF, Pellegrin JL, Ranchin V, Schaefferbeke T, Dehais J, Longy-Boursier M, et al. Th1 (IL-2, interferon-gamma [IFN- $\gamma$ ]) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). *Clin Exp Immunol* 1999;115:189-95.
- Richaud-Patin Y, Alcocer-Varela J, Llorente L. High levels of Th2 cytokine gene expression in systemic lupus erythematosus. *Rev Invest Clin* 1995;47:267-72.
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
- Sumida T, Sakamaki T, Yonaha F, Maeda T, Namekawa T, Nawata Y, et al. HLA-DR alleles in patients with Sjogren's syndrome over-representing V $\beta$ 2 and V $\beta$ 13 genes in the labial salivary glands. *Br J Rheumatol* 1994;33:420-4.
- Lanzillo JJ. Chemiluminescent nucleic acid detection with digoxigenin-labeled probes: a model system with probes for angiotensin converting enzyme which detect less than one attomole of target DNA. *Anal Biochem* 1991;194:45-53.
- Massengill SF, Goodenow MM, Sleasman JW. SLE nephritis is associated with an oligoclonal expansion of intrarenal T cells. *Am J Kidney Dis* 1998;31:418-26.
- Mostoslavsky G, Fischel R, Yachimovich N, Yarkoni Y, Rosenmann E, Monestier M, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. *Eur J Immunol* 2001;31:1221-7.
- Murata H, Kita Y, Sakamoto A, Matsumoto I, Matsumura R, Sugiyama T, et al. Limited TCR repertoire of infiltrating T cells in the kidneys of Sjogren's syndrome patients with interstitial nephritis. *J Immunol* 1995;155:4084-9.
- Min DJ, Cho ML, Cho CS, Min SY, Kim WU, Yang SY, et al. Decreased production of interleukin-12 and interferon- $\gamma$  is associated with renal involvement in systemic lupus erythematosus. *Scand J Rheumatol* 2001;30:159-63.
- Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E, et al. Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. *Arthritis Rheum* 1999;42:1644-8.
- Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. *Arthritis Rheum* 2001;44:2097-106.
- Santiago ML, Fossati L, Jacquet C, Muller W, Izui S, Reininger L. Interleukin-4 protects against a genetically linked lupus-like autoimmune syndrome. *J Exp Med* 1997;185:65-70.

## Conserved CDR 3 region of T cell receptor BV gene in lymphocytes from bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis

N. SHIMIZUDANI\*†, H. MURATA\*, H. KEINO\*, S. KOJO\*, H. NAKAMURA†, Y. MORISHIMA‡, T. SAKAMOTO‡, M. OHTSUKA‡, K. SEKISAWA‡, M. SUMIDA§, T. SUMIDA\* & T. MATSUOKA†  
\*Department of Internal Medicine, University of Tsukuba, Tsukuba, †Fifth Department of Internal Medicine, Tokyo Medical College, Ibaraki, ‡Division of Pulmonary Medicine, Department of Internal Medicine, University of Tsukuba, Tsukuba, and §Department of Anaesthesiology, Juntendo University, Tokyo, Japan

(Accepted for publication 25 February 2002)

### SUMMARY

Idiopathic pulmonary fibrosis (IPF) is an inflammatory lung disease characterized by the accumulation of inflammatory cells and deposition of collagen, resulting in lung remodelling. High numbers of T cells are present in bronchoalveolar lavage fluid (BALF) of IPF patients, although the characteristics of these cells are yet to be determined. To elucidate the pathogenic mechanisms of IPF, we analysed the T cell receptor (TCR) of BALF lymphocytes in three patients with IPF and three healthy subjects as control. TCR repertoire of BALF lymphocytes and T cell clonality were examined by family PCR and Southern blot analysis, and single-strand conformation polymorphism (SSCP), respectively. We observed that the TCR repertoire in the lung was heterogeneous, both in the control subjects and three patients with IPF. SSCP analysis demonstrated an increase in the number of accumulated T cell clones in BALF of two of the three patients, but not in the healthy subject. Furthermore, junctional sequence analysis showed the presence of conserved amino acid motifs (ETGRSG, LxG, QGQ, GxQP, GRxG, VAR, PGT, GTI, GGT, TGR, LxLxQ, SGQ) in the TCR-CDR 3 region of BAL lymphocytes in patients with IPF, whereas only two amino acid motifs (VTTG, GGE) were found in the control. Our findings suggest that T cells in BALF of patients with IPF expand oligoclonally in the lung, suggesting antigen stimulation of these cells.

**Keywords** clonality IPF pathogenesis T cell receptor T lymphocytes

### INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive pulmonary disorder, associated with both inflammation and fibrosis of the lung parenchyma [1,2]. Recent advances in biotechnology in the field of bronchoalveolar lavage (BAL) have provided considerable information on the cellular components of alveoli in this disease [3–5]. Pulmonary damage and fibrosis represent the consequences of immune response and inflammatory process. Previous studies have shown that lymphocytes (especially T cells) and alveolar macrophages play a central role in the pathogenesis of IPF, although the mechanism that triggers these cells has not been elucidated [6–8].

T cells recognize antigens in the context of MHC on antigen-presenting cells (APC) through an antigen receptor, the T cell receptor (TCR). Several groups investigating TCR genes in

autoimmune diseases such as rheumatoid arthritis [9], Sjögren's syndrome [10,11] and multiple sclerosis [12], among other diseases, have demonstrated that T cells accumulate oligoclonally in the inflamed lesion. Furthermore, conserved amino acid motifs have been observed in the CDR3 region of TCR gene, whereas there was no skewed usage of TCR genes [10–13].

Several studies have examined TCR genes of BAL fluid (BALF) T cells in patients with various lung diseases such as sarcoidosis and bronchial asthma. Moller and colleagues [14] demonstrated an increased number of TCR BV8 T cells in BALF of patients with sarcoidosis. Zissel *et al.* [15] showed the predominant usage of TCR BV5, BV8, BV12, BV13S3 and BV19 genes in BALF. Bellocq and coworkers [16] found a number of TCR BV19-positive T cells in BALF of patients with sarcoidosis. In asthmatic patients, Hodges *et al.* [17] reported expansion of TCR BV5S2/3-positive T cells in BALF. In contrast, there was no dominant usage of TCR BV genes in BALF T cells in patients with non-atopic asthma [18]. These findings support the hypothesis that BALF T cells of patients with sarcoidosis and atopic bronchial asthma may be induced by antigen on antigen-presenting cells. To date, there are no reports on the TCR

Correspondence: Prof Takayuki Sumida, Department of Internal Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.

E-mail: tsumida@md.tsukuba.ac.jp

gene of BALF T cells, or possible triggering factors in patients with IPF.

The present study was conducted in order to investigate the pathogenesis of IPF. Our experiments included an analysis of the TCR BV repertoire and clonality of T cells infiltrating the lung. Our results showed that T cells in BALF of patients with IPF expand oligoclonally, suggesting antigen-driven stimulation. Furthermore, highly conserved amino acid sequence motifs were identified in the TCR BV CDR3 region of accumulated BALF T cells. These findings indicate that BALF T cells in patients with IPF recognize a limited epitope on antigens. Based on these findings, we discuss possible pathogenic mechanisms of IPF.

## MATERIALS AND METHODS

### Patients and histological examination

Three patients with IPF were referred to Tokyo Medical University Hospital. Each individual met the criteria for IPF diagnosis, including clinical features, laboratory findings on chest X-ray and chest CT and endoscopic biopsies. We also recruited three healthy subjects who had no respiratory-related complaints and a negative chest X-ray. The clinical characteristics of the three patients with IPF and the healthy subjects are summarized in Table 1. Written informed consent was obtained from all patients. A transbronchial lung biopsy was performed, and the tissue was stained with haematoxylin and eosin. No open lung biopsy was performed. Typing of HLA-DR alleles was performed using PCR combined with dot-blot hybridization with sequence-specific oligonucleotide probes (PCR-SSOP) following the protocol of the Eleventh Histocompatibility Workshop [10].

### Bronchoalveolar lavage and peripheral blood lymphocytes

BAL was performed on the involved lung segment (right lower lobe and posterior segment) of the three patients with IPF and

three healthy control subjects. After topical anaesthesia, the fiberoptic bronchoscope (Olympus type BF20, Olympus Co., Tokyo, Japan) was advanced into the described segment and wedged, and 50 ml sterile 0.9% saline at 37°C was injected through the bronchoscope. The latter process was performed three times. The volume of BALF recovered from the involved segment was approximately 100 ml. Cells in BALF were passed through sterile gauze to remove debris. BALF from patients was centrifuged at 20 g and 4°C for 10 min, and washed twice with PBS. Following cell count, part of the cell mass was subjected to flow cytometric analysis. A number of cells ( $2 \times 10^5$ ) were stained with MoAb against Leu 4 (anti-CD3), Leu 3a (anti-CD4) and Leu 2a (anti-CD8) (Becton Dickinson, Mountain View, CA, USA). After flow cytometry, PBLs from patients with IPF were obtained by Ficoll-Hypaque density gradient centrifugation, and analysed immediately.

### PCR, Southern blot analysis and SSCP

Total RNA from BALF cells was prepared with Isogen (Nippon Gene Co., Tokyo, Japan). PCR and cDNA synthesis were performed as described previously by Sumida *et al.* [11]. Briefly, first-strand cDNA was synthesized from 1 µg total RNA in a 20-µl reaction mixture containing an oligo(dT) primer by avian myeloblastosis virus reverse transcriptase. Amplification was performed with *Taq* polymerase in 50 µl standard buffer, using 0.2 µl cDNA (corresponding to 10 ng total RNA), with primers specific for 20 different TCR BV genes and BC gene. Sequences of the primers were obtained from previously published data [10]. Denaturing was performed at 95°C for 1.5 min, annealing at 60°C for 1.0 min and extension at 72°C for 1.0 min for 30 cycles in a DNA Thermal Cycler (Perkin-Elmer Corporation, Norwalk, CT, USA). One-tenth of each amplified PCR product was subjected to 2% agarose gel electrophoresis and transferred to a nylon membrane. Membranes were hybridized further with

Table 1. Characteristics of study population

	IPF-1	IPF-2	IPF-3	HS-1	HS-2	HS-3
Age (years)	70	65	80	52	32	28
Sex	M	F	M	M	M	M
Smoking	(+)	(-)	(+)	(+)	(+)	(-)
%VC (%predicted value)	97.7	80.5	106.9	ND	118.0	133.4
FEV1%	79.5	88	77.3	ND	80.5	97.4
%DLco	48.2	57.9	74.6	ND	91.7	90.9
PaO <sub>2</sub> (mmHg)	89.7	85.9	81.3	ND	ND	ND
Chest radiograph						
diffuse reticular infiltrate pattern	(+)	(+)	(+)	(-)	(-)	(-)
BAL analyses						
Total cell count ( $\times 10^5$ /ml)	5	1.2	7	1	2.6	0.8
Differential count (%)						
Macrophages	87.2	81.7	92.1	90.5	93.0	90.0
Lymphocytes	3.7	15.2	4.5	3.2	3.5	8.0
Neutrophils	6.8	2.9	1.8	4.9	3.0	2.0
Eosinophils	2.3	0.2	1.6	1.4	0.5	0
CD4/CD8 ratio	1.9	1.4	2.3	2.2	0.6	4.7
Absolute number of lymphocytes*	1.9	1.8	3.2	0.3	0.9	0.6

Diagnosis of IPF was based on clinical criteria for IPF defined by The Ministry of Health and Welfare research group in Japan. \* $\times 10^6$ /ml.

digoxygenin-labelled TCR BC probe, and visualized using the DIG luminescent detection kit (Boehringer Mannheim, Mannheim, Germany). The digoxigenin-labelled TCR BC probe was synthesized employing the PCR DIG probe synthesis kit (Boehringer Mannheim), with 5'-TCR BC (5'-GAGGATCTGA GAAATGTGACT-3') and 3'-TCR BC (5'-CAAGCACACAC GAGGGTAGCCT-3') primers. For individual single-strand conformation polymorphism (SSCP) assays, amplified DNA was diluted (1:20) in a denaturing solution (95% formamide, 10 mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol) at 90°C for 2 min. Diluted samples (2:1) were subjected to electrophoresis in non-denaturing 5% polyacrylamide gels containing 10% glycerol [19]. Gels were run at 35W constant power for 2 h. Following electrophoresis, DNA was transferred to Immobilon-S (Millipore Intertech, Bedford, MA, USA) and hybridized with biotinylated TCR BC probe (5'-A (AC) AA (GC) GTGTTCCACCCGAG GTCGCTGTGTT-3'), streptavidin, biotinylated alkaline phosphatase and a chemiluminescent substrate system (Plex™ Luminescence kit, Millipore).

#### Sequencing of cDNA encoding TCR BV genes

Complementary DNA, encoding TCR BV genes from BALF and PBLs, was purified from polyacrylamide gels for subjection to SSCP and amplified by PCR using the primers described above. PCR products were ligated to plasmids using the TA cloning kit (Invitrogen, San Diego, CA, USA), transformed into competent INVαF' *Escherichia coli* cells and grown under appropriate conditions. After selection of TCR BC-positive colonies, plasmid DNA was purified by alkaline lysis for DNA sequencing. Sequencing reactions were performed using an automated DNA sequencer (model 377 A, Applied Biosystems, Foster City, CA, USA).

## RESULTS

#### Heterogeneous TCR BV repertoire of BALF T cells in patients with IPF

To analyse the pathogenesis of IPF, we examined the TCR repertoire of BALF T cells from three patients with IPF (IPF-1, -2, and -3) using the family PCR method. PBLs from identical patients were used as a control. Clinical profiles of IPF patients are summarized in Table 1. Chest CT revealed diffuse reticulonodular opacities, honeycombing and ground-glass attenuation. Histological examination of lung biopsies from patients with IPF showed a large number of mononuclear cells in the inflamed alveolar

septa. The pathological changes in the interstitial septa, alveolar spaces, bronchial mucosa and pleura were similar to those in lungs with UIP. Infectious agents or parasites were not observed, and there was no evidence of vasculitis in biopsy specimens. TCR analysis showed expression of the majority of TCR BV family genes in both BALF T cells and PBL in all patients (Fig. 1). These results suggest that the TCR BV repertoire of T cells in the lung is heterogeneous and that there is no restricted predominant usage of TCR BV genes. HLA typing of two patients with IPF showed that one was the DR B1\*0405, 0405 allele and the other was the DR B1\*0901, 1502 allele.

#### Lung-specific T cell clones in patients with IPF

TCR BV genes in BALF and peripheral T cells were examined by PCR-SSCP in order to investigate the clonality of pulmonary T cells in patients with IPF. Lung-specific bands that were found in several TCR BV genes of the three IPF patients. These bands were detected mainly in TCR BV 3, 11 and 15 genes. The number of bands encoding TCR BV genes in the lung is summarized in Table 2. We observed a significant increase in the number of expanded clones in BALF from IPF-1 and -3 patients (26 and 24 clones), compared with the healthy subjects (six clones) ( $P < 0.05$ ). In contrast, there was no difference in the number of T cell clones in the lung between IPF-2 patients and healthy controls. These results suggest that some T cells accumulate in the lungs of patients with IPF, suggesting that these cells proliferate by antigen stimulation.

#### Conserved amino acid sequence motifs in the CDR3 region of TCR BV genes from BALF-specific T cells of IPF patients

To examine the amino acid sequences of the CDR3 region in the TCR BV gene, we focused on the lung-specific T cell clones on SSCP analysis. DNAs encoding the TCR BV genes from BALF-specific bands were eluted from gels, following which the corresponding CDR3 regions were sequenced. As shown in Table 3, the CDR3 region of the lung-specific accumulated T cell clones contained conserved amino acid motifs. A LAXG motif was found in BV3-2 and BV6-1 clones from IPF-1 and BV8-2 and BV16-1 clones from the IPF-2 patient. Furthermore, in the IPF-2 patient, QQQ, GxQP, GRxG and EIGRSG motifs were found in BV6-1 and BV9-1, BV11-1 and BV11-2, BV15-2, BV 20-1 and BV20-2, and BV20-1 and BV20-2, respectively. For the IPF-3 patient, VAR, PGT, TGR, SGQ, LxLxQ, GGT, PGT, GTI sequences were observed in BV1-1 and BV1-2, BV2-1 and BV15-1, BV2-2 and BV18-2, BV3-1 and BV3-2, BV3-1 and BV11-1, BV10-2 and

**Table 2.** Accumulated T cell clones in BALF of patients with IPF

TCR BV gene	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	Total
IPF -1	0	0	2	0	0	3	0	0	3	1	7	0	0	0	2	0	2	2	4	0	26
IPF -2	1	1	1	0	0	0	0	1	0	0	1	0	0	0	1	1	0	0	0	1	8
IPF -3	1	1	3	0	1	1	1	0	0	2	1	0	3	3	3	1	0	2	0	1	24
Healthy subject 1	1	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	2	6
Healthy subject 2	0	0	0	0	0	1	0	1	0	0	1	0	0	1	1	0	0	1	0	0	6
Healthy subject 3	0	0	1	0	0	0	1	0	0	1	0	0	0	1	0	0	0	1	0	1	6

Numbers represent T cell clones accumulated in BAL from patients with IPF. The distinct bands encoding TCR BV genes on SSCP were described as the number of BAL-specific T cell clones.




Fig. 1. TCR BV gene repertoire of BALF T cells from three patients with IPF and three healthy subjects. PCR, Southern blot analysis and SSCP methods are described in Patients and methods. The numbers indicate the family of TCR BV genes.

BV20-1, BV10-2 and BV15-1, and BV14-2 and BV16-1, respectively. In contrast, BALF-specific bands of healthy subjects revealed only two motifs, VTGG and GGE. A VTGG motif was found in BV1-2 clone from healthy subject 1 and BV11-2 clone from healthy subject 2 and a GGE motif was found in BV2-1 clone from healthy subject 1 and BV18-2 clone from healthy subject 2 (Table 3). These amino acid motifs were not detected in patients with IPF. The conserved amino acids motifs in TCR BV CDR3 region of BAL T cells in patients with IPF was summarized in Table 4. These findings suggest that accumulated T cells

in the lungs of patients with IPF recognize a limited epitope on antigens.

### DISCUSSION

IPF is an inflammatory lung disease characterized by the accumulation of lymphocytes and other inflammatory cells, resulting in lung remodeling. T cells comprise the major population of lymphocytes in pulmonary tissue and BALF [15,16,21]. In the present study of TCR genes, we provide evidence that some T

Table 3. TCR BV CDR3 region of BAL T cells in patients with IPF

## (1) IPF-1

	V	N-D-N	J	
Clone	92	96	106	
BV3-1	C A S S TGTGCCAGCAGT	L G V S A N TTAGGAGTATCAGCGAAC	T E A ACTGAAGCT	BJ1S1
BV3-2	C A S S TGTGCCAGCAGT	L A T G D TTAGCGACAGGGGAT	G Y GGCTAC	BJ1S2
BV6-1	C A S TGTGCCAGC	G L A Q G GGTTTAGCCCAGGGT	Q P Q CAGCCCCAG	BJ1S5
BV6-2	C A S S TGTGCCAGCAGC	V GTGGT	G Y GGCTAC	BJ1S2
BV9-1	C A S S TGTGCCAGCAGC	Q G Q G T CAAGACAGGGAACGACG	N T E A AACACTGAAGCT	BJ1S1
BV9-2	C A S S TGTGCCAGCAGC	P G CCAGGC	T E A ACTGAAGCT	BJ1S1
BV11-1	C A S TGTGCCAGC	S G R M TCGGGACGGATG	N T E A AACACTGAAGCT	BJ1S1
BV11-2	C A S TGTGCCAGCA	V R A G H GTCCGAGCGGGACATAT	Q P Q CAGCCCCAG	BJ1S5
BV15-1	C A T S TGTGCCACCAGT	D P G F GATCCCGGATTT	T E A TACGAGCAG	BJ2S7
BV15-2	C A T S TGTGCCACCAGT	D S V GACTCCGTC	T D T Q ACAGATACGCAG	BJ2S3
BV17-1	C A S S TGTGCCAGTAGT	L R L S G K S D CTACGACTGTCCGGGAAATCAGAC	Q P Q CAGCCCCAG	BJ1S5
BV17-2	C A S S TGTGCCAGCAGT	L S N T TTATCGAATACA	E T V GAGACCCAG	BJ2S5
BV18-1	C A S S TGTGCCAGCTCA	P R V S CCACGGGTTTCC	E Q GAGCAG	BJ2S7
BV18-2	C A S S TGTGCCAGCTCA	L R W A P A CTGCGGTGGGCCCCGGCT	Y E Q TACGAGCAG	BJ2S7
BV19-1	C A S TGTGCCAGCAG	P S G CCAAGCGCT	E Q GAGCAG	BJ2S1

## (2) IPF-2

	V	N-D-N	J	
Clone	92	96	106	
BV1-1	C A S S TGTGCCAGCAGC	V S D A G A GTTTCGGACGCGGGGCT	Q P Q CAGCCCCAG	BJ1S5
BV1-2	C A S S TGTGCCAGCAGC	V E G Q G R GTAGAAGGACAGGGAAGA	D T Q GATACGCAG	BJ2S3
BV2-1	C S A S TGCACTGCTAGT	V T S L I GTGACTAGTTTGATT	I Q ATACAG	BJ2S1

Table 3. Continued

(2) IPF-2 Continued.

	V	N-D-N	J	
Clone	92	96		106
BV3-1	C A S S TGTGCCAGCAGT	F G Q TTTGGACAG	N T E A AACACTGAAGCT	BJ1S5
BV3-2	C A S S TGTGCCAGCAGC	R D I Y CGCGACATATAC	T E A ACTGAAGCT	BJ1S1
BV8-1	C A S TGTGCCAGCGG	T L R ACCCTTAGGC	Y E Q TACGAGCAG	BJ2S7
BV8-2	C A S S TGTGCCAGCAGT	L A L G A CTGGCTTTGGGGGCT	Y G Y TATGGCTAC	BJ1S2
BV11-1	C A S TGTGCCAGCA	G G Q GAAGGGGGTAT	Q P Q CAGCCCCAG	BJ1S5
BV11-2	C A S R TGTGCCAGCAGA	M G F ATGGGGTTT	Q P Q CAGCCCCAG	BJ1S5
BV15-1	C A T S TGTGCCACCTCT	D R L I G P GACCGATTGATGGGCCCT	N E K L AATGAAAACTG	BJ1S4
BV15-2	C A T S TGTGCCACCAGT	E T G R Q G T GAAACCGGGAGACAGGGTACC	T G E L CCAGGGGAGCTG	BJ2S2
BV16-1	C A S S TGTGCCAGCAGC	Q A A P G L A R CAAGCGGCTCCGGGACTGGCACGA	G E L GGGGAGCTG	BJ2S2
BV20-1	C A TGTGCC	S R E I G R S G AGCAGAGAAAATAGGTAGGAGTGGG	N E Q AATGAGCAG	BJ2S1
BV20-2	C A W S TGTGCCAGCAGT	E I G R S G S K GAAATAGGTAGGAGCGGGAGTAAG	N E Q AATGAGCAG	BJ2S1

(3) IPF-3

	V	N-D-N	J	
Clone	92	96		106
BV1-1	C A S S TGTGCCAGCAGC	V A R T S I N GTAGCGAGGACTAGCATTAAT	E Q GAGCAG	BJ2S5
BV1-2	C A S S TGTGCCAGCAGC	V A R G GTAGCGCGGGGC	S E A TCTGAAGCT	BJ1S1
BV2-1	C A A R TGTAGTGCTAGA	P G T CCAGGGAGC	D Y G Y GACTATGGCTAC	BJ2S1
BV2-2	C A A TGCAAGTCC	R E T G R AGGGAAACAGGCCGA	D T Q GATACCCAT	BJ2S3
BV3-1	C A S S TGTGCCAGCAGT	S G Q L V AGCGGACAGCTACAA	L T Q GAGACCCAG	BJ2S5
BV3-2	C A S S TCAGGACAAGAG	S G Q E T TCAGGACAAGAGACC	Q CAG	BJ2S3
BV3-3	C A S S TGTGCCAGCAGT	L C Q A P F N TTATGGCAGGCCCTTCAAT	Q CAG	BJ2S7
BV5-1	C A S S TGTGCCAGCAGC	S K Y R E P G TCCAAATACAGGGAACCGGGA	E Q GAGCAG	BJ2S7

Table 3. Continued

(3) IPF-3 Continued.

	V	N-D-N	J	
Clone	92	96	106	
BV6-1	C A S S TGTGCCAGCAGC	S L T G V F N TCGCTAACGGGAGTCTCAAT	N Q AATCAA	BJ2S1
BV7-1	C A S GCCAGCAGC	S I Q G S T CTGATACAGGGTCTACT	G Y GGCTAC	BJ1S2
BV10-1	C A S S TGTGCCAGCAGC	K A P G Q G P R C AAAGCACCGGGACAGGGTCCCTCGCTGC	A GCT	BJ1S1
BV10-2	C A S S TGTGCCAGCAGC	M <span style="border: 1px solid black;">G G T</span> G D <span style="border: 1px solid black;">P G</span> T Q ATGGGTGGGACAGGGACCCGGGG	Q ACCCAG	BJ2S3
BV11-2	C A S TGTGCCAGC	S E <span style="border: 1px solid black;">L</span> T <span style="border: 1px solid black;">L</span> I <span style="border: 1px solid black;">Q</span> AGTGAAC TAACCGATATCCAA	E T Q GATACCCAG	BJ2S3
BV13-1	C A S S TGTGCCAGCTCT	L L G TTGCTGGGG	I S P L GATTCACCCCTC	BJ1S1
BV13-2	C A G S TGTGCCGGCTCG	L G V D CTCGGGTGGAT	G N T I GGAAACACCATA	BJ1S3
BV13-3	S A S S AGTGCCAGCAGT	C N T G A G N TCAAACACAGGGGCGGGAAT	S P L TCACCCCTC	BJ1S6
BV13-3	C A S A TGTGCCTCCGCA	S L A Y T TCCCTTGCGTATACG	E Q GAGCAT	BJ2S7
BV14-1	C A S S TGTGCCAGCAGT	P P A A G CCCCCTGCGGCAGGG	L N T E A TTGAACACTGAAGCT	BJ1S1
BV14-2	C A S S TGGGCCAGCAGT	Y R R S E <span style="border: 1px solid black;">G T I</span> T TATCGCCGATCCGAGGGGACTATAACC	Y TAC	BJ1S2
BV14-3	C A S S TGTGCCAGCAGT	F G G TTTGGCGGG	P Y N Q CCCTACAATGAG	BJ1S2
BV15-1	C A S S TGTGCCACCAGT	<span style="border: 1px solid black;">P G T</span> S G R CCCGGGACTAGCGGGAGG	S D T Q TCAGATACGCAG	BJ2S3
BV15-2	C A S S TGTGCCACCAGT	D GAT	S G E L TCCGGGGAGCTG	BJ2S2
BV15-3	C A S S TGTGCCACCAGT	A A S GCCGCCAGC	A F D Q GCCTACGATCAG	BJ2S7
BV16-1	C A S S TGTGCCAGCAGC	Q V G <span style="border: 1px solid black;">G T I</span> CAAGTCGGGGGACGATA	R CGA	BJ1S1
BV18-1	C A S TGTGCCAGCTC	S R G V TCGCGGGGGGTCC	N E Q AATGAGCAG	BJ2S1
BV18-2	C A S S TGTGCCAGCTCA	P T Q <span style="border: 1px solid black;">T G R</span> CCGACACAGACAGGACGG	N E K L AATGAAAACTG	BJ1S4
BV20-1	C A S D TGTGCCTGGGAT	<span style="border: 1px solid black;">G G T</span> C L GGTGGGACATGCCTC	T E A ACTGAAGCT	BJ1S1



Table 3. Continued

(4) healthy subject-1

	V				N-D-N				J							
Clone	92				96				106							
BV1-1	C	A	S	S	A	G	T			N	Q	E	T	Q	BJ2S5	
BV1-2	C	A	S	S	V	T	G	G	S	L	N	E	Q			BJ2S1
BV2-1	C	S	A	K	G	E	R	G	G	E	Q				BJ2S1	
BV2-2	C	S	A	R	I	G	T			Q	E	T	Q		BJ2S5	
BV2-3	C	S	A		D	R	N			Q	E	T	Q		BJ2S5	
BV2-4	C	S	A	S	K	T	G	T			G	E	L		BJ2S2	
BV8-1	C	A	S	S	L	G					Y	E	Q		BJ2S7	
BV20-1	C	A	W		K	R	E	S			E	Q				BJ2S1
BV20-2	C	A			F	T	G	Q	G	A	S	N	Q	P	Q	BJ1S5
BV20-3	C	A			S	R	D	R	G	L	N	Q	P	Q		BJ1S5

(5) healthy subject-2

	V				N-D-N				J								
Clone	92				96				106								
BV6-1	C	A	S	S	H	S	G	R	E	R	Y	N	E	Q	BJ2S1		
BV8-1	C	A	S		Q	G					M	N	T	E	A	BJ1S1	
BV8-2	C	A	S	S	F	G	A			E	Q				BJ2S7		
BV8-3	C	A	S	S	F	S	G	T	S	G	N	E	Q			BJ2S1	
BV11-1	C	A	S		V	M	M	T	G			T	E	A		BJ1S1	
BV11-2	C	A	S		V	T	G	G			T	G	E	L		BJ2S2	
BV14-1	C	A	S	S	L	V	G	G	R			T	D	D	Q	BJ2S3	
BV14-2	C	A	S	S	W	R	G			T	G	E	L		BJ2S2		
BV15-1	C	A	T	S	G	P	A	D	E	N	G	E	Q			BJ2S1	
BV15-2	C	A	T	S	D	G					Y	E	Q		BJ2S7		
BV18-1	C	A	S	S	P	G	A	G			S	S	Y	E	Q	BJ2S7	
BV18-2	C	A	S	S	P	Q	G	G	E			Q			BJ2S1		
BV18-3	C	A	S	S	P	P	G	P	L			S	Y	N	E	Q	BJ2S1

(6) healthy subject-3

	V				N-D-N				J								
Clone	92				96				106								
BV3-1	C	A	S	S	P	E	P	Q	G	V	R	T	Q		BJ2S5		
BV7-1	A	S	S		Y	S	S	G			Y	E	Q		BJ2S7		
BV7-2	A	S	S	Q	D	G	G	G	G			N	T	G	E	L	BJ2S2
BV10-1	C	A	S	S	S	P	L	G	A			P	Q			BJ1S5	
BV10-2	C	A	S	S	K	T	E	R	E			Y	E	Q		BJ2S7	

Table 3. Continued

(6) healthy subject-3 Continued.

Clone	V				N-D-N					J				
	92	96			106									
BV14-1	C	A	S	S	L	S	E	M	G	N	E	Q	BJ2S1	
BV18-1	C	A	S	S	R	P	G	S	G	T	D	T	Q	BJ2S3
BV18-2	C	A	S	S	Q	T	E			N	I	Q	BJ2S4	
BV20-1	C	A	W	S	P	L	A	L		E	T	Q	BJ2S5	
BV20-2	C	A	W		A	L	G	I	A	S	N	E	Q	BJ2S1

The single letter amino acid sequences at 3' position of TCR BV, CDR3, and 5' position of the J region are given. Identical sequences are boxed.

Table 4. Conserved amino acid motifs in TCR BV CDR3 region of BAL T cells in patients with IPF

(1) IPF	
LAXG	(IPF-1; BV3-2, BV6-1, IPF-2; BV8-2, BV16-1)
QGG	(IPF-1; BV6-1, BV9-1)
GxQP	(IPF-2; BV11-1, BV11-2)
GRxG	(IPF-2; BV15-2, BV 20-1, BV20-2)
EIGRSG	(IPF-2; BV20-1, BV20-2)
VAR	(IPF-3, BV1-1, BV1-2)
PGT	(IPF-3, BV2-1, BV15-1)
TGR	(IPF-3, BV2-2, BV18-2)
SGQ	(IPF-3, BV3-1, BV3-2)
LxLxQ	(IPF-3, BV3-1, BV11-1)
GGT	(IPF-3, BV10-2, BV20-1)
PGT	(IPF-3, BV10-2, BV15-1)
GTI	(IPF-3, BV14-2, BV16-1)
(2) Healthy subject	
VTGG	(healthy subject 1; BV1-2, healthy subject 2; BV11-2)
GGE	(healthy subject 1; BV2-1, healthy subject 2; BV18-2)

cells accumulate in BALF, suggesting that cells in pulmonary lesions might expand by antigen stimulation in the context of HLA, rather than stimulation by superantigen, as suggested previously [20,21]. This conclusion is in agreement with the results of Lympny *et al.* [22], where the TCR repertoire of T cells in lung biopsy samples and BALF was analysed using RT-PCR, and individual TCR AV and BV expression bias was observed in subjects with fibrosing alveolitis. The findings are also similar to those observed in T cells from the lungs of patients with sarcoidosis [14-16] and atopic bronchial asthma [17]. Considered together, these findings suggest that the pathogenesis of IPF occurs in two steps. The first step includes the presentation of antigens on the HLA molecule. This is followed by accumulation of reactive T cells in the pulmonary lesion, which in turn induces inflammation, resulting in pulmonary fibrosis.

Using flow cytometry, Gruber *et al.* [23] showed a high proportion of CD8<sup>+</sup> T cells, low proportion of CD4<sup>+</sup> T cells and no change in  $\gamma\delta$  T cells in IPF, compared with sarcoidosis. However, we observed a greater increase in the number of CD4<sup>+</sup> T cells

compared to CD8<sup>+</sup> T cells, while  $\gamma\delta$  T cells (data not shown) were not detected in BALF of all three patients (data not shown). The discrepancy in these results may be due either to individual observations during different stages of IPF or the presence of distinct pathogenic antigens.

Several conserved amino acid motifs were found in the CDR3 region of the TCR BV gene in clonally expanded BALF T cells of patients with IPF, suggesting that these T cells recognize highly limited epitopes on the antigen. The phenomenon appears to be disease-specific, because there were no corresponding conserved amino acids in BALF T cells of the control subjects. The restricted T cell epitope on the antigen was not dependent on HLA, because HLA-DR of the two IPF patients varies widely among the two patients. This finding suggests the presence of dominant and common T cell epitopes on the antigen. Although this study is dependent on small numbers of IPF patients, a further large-scale study would be necessary to confirm our conclusion.

The identity of antigens recognized by accumulated T cells in BALF of patients with IPF remains to be established. While previous studies have recognized candidate antigens in IPF, no direct evidence has been presented to date [24,25]. Recently, viral proteins such as cytomegalovirus and Epstein-Barr virus (EBV) proteins were considered [26-30]. Antibodies against cytomegalovirus and EBV were detected in patients with pulmonary fibrosis [27,28] and their viral products were expressed in immunostained pulmonary tissues [26,30]. Moreover, DNA and mRNA encoding cytomegalovirus and EBV were detected in patients with pulmonary fibrosis by RT-PCR and ISH [29,30]. These observations suggest that particular viral products are antigens recognized by T cells in pulmonary lesions, and may therefore play a crucial role in the pathogenesis of pulmonary fibrosis.

Therefore, determination of the amino acid sequences of T cell epitopes of the antigen is essential before any vaccine using an analogue peptide of the antigen is used for antigen-specific regulation of IPF.

#### ACKNOWLEDGEMENTS

We thank Miss Miyuki Nishihara for technical assistance, and Dr F. G. Issa (www.word-medex.com.au) for critical reading of the manuscript.

## REFERENCES

- 1 Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause. *N Engl J Med* 1984; **310**:235–44.
- 2 Crystal RG, Gedek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghaku GW. Interstitial lung disease. current concepts of pathogenesis, staging, and therapy. *Am J Med* 1981; **70**:542–68.
- 3 Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationship of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. *Am Rev Respir Dis* 1981; **124**:1–8.
- 4 Haslam PL, Turton CW, Lukoszik A *et al.* Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and relation to therapy. *Thorax* 1980; **35**:328–39.
- 5 Haslam PL, Turton CW, Heard B *et al.* Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. *Thorax* 1980; **35**:9–18.
- 6 Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance and pathologic classification. *Am J Respir Crit Care Med* 1998; **157**:130–15.
- 7 Bjoraker JA, Ryu JH, Edwin MK *et al.* Prognostic significance of histopathological subsets in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998; **157**:199–203.
- 8 Ryu JH, Colby TV, Hartmann TE. Idiopathic pulmonary fibrosis: current concepts. *Mayo Clin Proc* 1998; **11**:1085–101.
- 9 Paliard X, West SG, Lafferty JA *et al.* Evidence for the effects of a super antigen in rheumatoid arthritis. *Science* 1991; **253**:325–8.
- 10 Sumida T, Sakamaki T, Yonaha F *et al.* HLA-DR alleles in patients with Sjögren's syndrome over-representing Sjögren's syndrome Vb2 and Vb13 genes in the labial salivary glands. *Br J Rheumatol* 1994; **33**:42014.
- 11 Sumida T, Yonaha F, Maeda T *et al.* T cell receptor repertoire of infiltrating T cells in lips of Sjögren's syndrome patients. *J Clin Invest* 1992; **89**:681–5.
- 12 Kotzin BL, Karuturi S, Chou YK *et al.* Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. *Proc Natl Acad Sci USA* 1991; **88**:9161–5.
- 13 Wucherpfening KW, Ota K, Endo N *et al.* Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. *Science* 1990; **248**:1016–9.
- 14 Moller DR, Konishi K, Kirby M, Balbi B, Crystal RG. Bias toward use of specific T cell receptor beta-chain variable region in a subgroup of individuals with sarcoidosis. *J Clin Invest* 1988; **82**:1183–91.
- 15 Zissel G, Baumer I, Fleischer B, Schlaak M, Muller-Quernheim J. TCR V beta families in T cell clones from sarcoid lung parenchyma, BAL, and blood. *Am J Respir Crit Care Med* 1997; **156**:1593–600.
- 16 Bellocq A, Lecossier D, Pierre-Audigier C, Tazi A, Valeyre D, Hance AJ. T cell receptor repertoire of T lymphocytes recovered from the lung and blood of patients with sarcoidosis. *Am J Respir Crit Care Med* 1994; **149**:646–54.
- 17 Hodges E, Dasmahapatra J, Smith JL *et al.* T cell receptor V $\beta$  gene usage in bronchoalveolar lavage and peripheral blood T cells from asthmatic and normal subjects. *Clin Exp Immunol* 1998; **112**:363–74.
- 18 Umibe T, Kita Y, Nakao A *et al.* Clonal expansion of T cells infiltrating in the airways of non-atopic asthmatics. *Clin Exp Immunol* 2000; **119**:390–7.
- 19 Yamamoto K, Sakoda H, Nakajima T *et al.* Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. *Int Immunol* 1992; **4**:1219–23.
- 20 Jones CM, Lake RA, Wijeyekoon JB, Mitchell DM, du Bois RM, O'Hehir RE. Oligoclonal V gene usage by T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients. *Am J Cell Mol Biol* 1996; **14**:470–7.
- 21 Vissinga C, Springmeyer SC, Concannon P. TCR expression and clonality analysis in pulmonary sarcoidosis. *Hum Immunol* 1996; **48**:98–106.
- 22 Lympany PA, Southcott AM, Welsh KI, Boylston AW, du Bois RM. T-cell receptor gene usage in patients with fibrosing alveolitis and control subjects. *Eur J Clin Invest* 1999; **29**:173–81.
- 23 Gruber R, Pforte A, Beer B, Riethmuller G. Determination of gamma/delta and other T-lymphocyte subsets in bronchoalveolar lavage fluid and peripheral blood from patients with sarcoidosis and idiopathic fibrosis of the lung. *APMIS* 1995; **104**:199–203.
- 24 Ueda T, Ohta K, Suzuki N *et al.* Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. *Am Rev Respir Dis* 1992; **146**:266–8.
- 25 Kuwano K, Nomoto Y, Kunitake R *et al.* Detection of adenovirus EIA DNA in pulmonary fibrosis using nested polymerase chain reaction. *Eur Respir J* 1997; **10**:1445–9.
- 26 Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carrol KB, Woodcock AA. Epstein-Barr virus replication within pulmonary epithelial cells, in cryptogenic fibrosing alveolitis. *Thorax* 1995; **50**:1234–9.
- 27 Yonemaru M, Kasuga H, Kusumoto H *et al.* Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis. *Eur Respir J* 1997; **10**:2040–5.
- 28 Vergnon JM, Vincent M, de The G, Mornex JF, Weynants P, Brune J. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association. *Lancet* 1984; **ii**:768–71.
- 29 Wangoo A, Shaw RJ, Diss TC, Farrell PJ, du Bois RM, Nicholson AG. Cryptogenic fibrosing alveolitis. Lack of association with Epstein-Barr virus infection. *Thorax* 1997; **52**:888–91.
- 30 Jiwa M, Steenbergen RD, Zwaan FE, Kluin PM, Raap AK, Ploeg M. Three sensitive methods for the detection of cytomegalovirus in lung tissue of patients with interstitial pneumonia. *Am J Clin Pathol* 1990; **93**:491–4.

# Prevention of Experimental Autoimmune Encephalomyelitis by Transfer of Embryonic Stem Cell-Derived Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein Peptide along with TRAIL or Programmed Death-1 Ligand<sup>1</sup>

Shinya Hirata, Satoru Senju, Hidetake Matsuyoshi, Daiki Fukuma, Yasushi Uemura, and Yasuharu Nishimura<sup>2</sup>

Experimental autoimmune encephalomyelitis (EAE) is caused by activation of myelin Ag-reactive CD4<sup>+</sup> T cells. In the current study, we tested a strategy to prevent EAE by pretreatment of mice with genetically modified dendritic cells (DC) presenting myelin oligodendrocyte glycoprotein (MOG) peptide in the context of MHC class II molecules and simultaneously expressing TRAIL or Programmed Death-1 ligand (PD-L1). For genetic modification of DC, we used a recently established method to generate DC from mouse embryonic stem cells (ES cells) in vitro (ES-DC). ES cells were sequentially transfected with an expression vector for TRAIL or PD-L1 and an MHC class II-associated invariant chain-based MOG epitope-presenting vector. Subsequently, double-transfectant ES cell clones were induced to differentiate to ES-DC, which expressed the products of introduced genes. Treatment of mice with either of the double-transfectant ES-DC significantly reduced T cell response to MOG, cell infiltration into spinal cord, and the severity of MOG peptide-induced EAE. In contrast, treatment with ES-DC expressing MOG alone, irrelevant Ag (OVA) plus TRAIL, or OVA plus PD-L1, or coinjection with ES-DC expressing MOG plus ES-DC-expressing TRAIL or PD-L1 had no effect in reducing the disease severity. In contrast, immune response to irrelevant exogenous Ag (keyhole limpet hemocyanin) was not impaired by treatment with any of the genetically modified ES-DC. The double-transfectant ES-DC presenting Ag and simultaneously expressing immune-suppressive molecules may well prove to be an effective therapy for autoimmune diseases without inhibition of the immune response to irrelevant Ag. *The Journal of Immunology*, 2005, 174: 1888–1897.

Currently, corticosteroids and other immune suppressants are commonly used for treatment of subjects with autoimmune diseases. The medication with these drugs often leads to systemic immune suppression and consequent opportunistic infections. Thus, it is desirable to develop a therapeutic means to down-modulate immune responses in an Ag-specific manner without causing systemic immune suppression.

Experimental autoimmune encephalomyelitis (EAE),<sup>3</sup> an animal model for human multiple sclerosis, is characterized by neurological impairment resulting from demyelination in the CNS caused by myelin Ag-reactive CD4<sup>+</sup> T cells. This disease model is

induced by immunization with myelin Ags such as myelin oligodendrocyte glycoprotein (MOG). In the current study, we wanted to try to prevent MOG-induced EAE by treatment of mice with genetically modified dendritic cells (DC). We generated double-transfectant DC presenting MOG peptide in the context of MHC class II molecules and simultaneously expressing molecules with T cell-suppressive property. We tested a strategy to down-modulate the immune response in an Ag-specific manner by in vivo transfer of such genetically modified DC to prevent development of the disease.

For efficient presentation of MOG peptide in the context of MHC class II molecules, we used a previously devised expression vector in which cDNA for human MHC class II-associated invariant chain (Ii) was mutated to contain antigenic peptide in the class II-associated Ii peptide (CLIP) region (1). An epitope inserted in this vector is efficiently presented in the context of coexpressed MHC class II molecules (2). Because they are molecules with a T cell-suppressive property, we tested TRAIL and Programmed Death-1 ligand (PD-L1). TRAIL, a member of the TNF superfamily, is constitutively expressed in a variety of cell types, including lymphocytes, NK cells, and neural cells (3, 4). TRAIL<sup>-/-</sup> mice are hypersensitive to collagen-induced arthritis and streptozotocin-induced diabetes (5). PD-L1, a ligand for PD-1 and member of the CD28/CTLA-4 family, is expressed on DC, IFN- $\gamma$ -treated monocytes, activated T cells, placental trophoblasts, myocardial endothelium, and cortical thymic epithelial cells (6, 7). PD-1<sup>-/-</sup> mice spontaneously develop a lymphoproliferative/autoimmune disease, a lupus-like disease, arthritis, and cardiomyopathy (8, 9). Thus, abrogation of either of these two molecules make mice autoimmune prone, suggesting that these molecules play significant roles

Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Received for publication May 20, 2004. Accepted for publication December 8, 2004.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> This work was supported in part by Grants-in-Aid 12213111, 14370115, 14570421, and 14657082 from the Ministry of Education, Science, Technology, Sports, and Culture, Japan, and a Research Grant for Intractable Diseases from Ministry of Health, Labour and Welfare, Japan, and grants from the Tokyo Biochemical Research Foundation and Uehara Memorial Foundation, and by funding from Meiji Institute of Health Science.

<sup>2</sup> Address correspondence and reprint requests to Dr. Yasuharu Nishimura, Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto 860-8556, Japan. E-mail address: mxnishim@gpo.kumamoto-u.ac.jp

<sup>3</sup> Abbreviations used in this paper: EAE, experimental autoimmune encephalomyelitis; MOG, myelin oligodendrocyte glycoprotein; DC, dendritic cell; Ii, invariant chain; CLIP, class II-associated Ii peptide; PD-L1, Programmed Death-1 ligand; ES cell, embryonic stem cell; ES-DC, ES cell-derived DC; PLP, myelin proteolipid protein; MBP, myelin basic protein; IRES, internal ribosomal entry site; PCC, pigeon cytochrome c; KLH, keyhole limpet hemocyanin.

in maintaining immunological self-tolerance in physiological situations (10–18).

For introduction of multiple expression vectors into DC, we used a method for embryonic stem cell (ES cell)-mediated genetic modification of DC. Recently, we and another group established culture procedures to generate DC from mouse ES cells (2, 19). ES cell-derived DC (esDC or ES-DC) have the capacity comparable to bone marrow-derived DC to process and present protein Ags to T cells, stimulate naive T cells, and migrate to lymphoid organs in vivo (20, 21). A recent study using the method revealed the role of Notch signaling in differentiation of DC (22). For generation of genetically modified ES-DC, ES cells were transfected with expression vectors, and subsequently transfectant ES cell clones were induced to differentiate to DC, which expressed the products of introduced genes. Introduction of multiple exogenous genes by sequential transfection can readily be done with vectors bearing different selection markers (20).

In this study, we report that treatment of mice with ES-DC presenting MOG peptide in the context of MHC class II and simultaneously expressing TRAIL or PD-L1 significantly reduced the severity of EAE induced by immunization with the MOG peptide.

## Materials and Methods

### Mice

CBA, and C57BL/6 mice obtained from CLEA Japan or Charles River were kept under specific pathogen-free conditions. Male CBA and female C57BL/6 mice were mated to generate F<sub>1</sub> (CBF<sub>1</sub>) mice, and all in vivo experiments were done using CBF<sub>1</sub> mice, syngeneic to TT2 ES cells. Mouse experiments met with approval by Animal Research Committee of Kumamoto University.

### Peptides, protein, cell lines, and cytokines

The mouse MOG p35–55 (MEVGWYRSPFSRVVHLYRNGK), mouse myelin proteolipid protein (PLP) p190–209 (SKTSASIGSLCADARM YGVL), and mouse myelin basic protein (MBP) p35–47 (TGILDSI GRFFSG), were synthesized using the F-moc method on an automatic peptide synthesizer (PSSM8; Shimadzu) and purified using HPLC (23–25). Bovine MBP was purchased from Sigma-Aldrich. The ES cell line, TT2, derived from CBF<sub>1</sub> blastocysts, and the M-CSF-defective bone marrow-derived stromal cell line, OP9, were maintained, as described (2). L929, a fibroblast cell line originating from a C3H mouse was purchased from Japan Health Science Foundation (Osaka, Japan). Recombinant mouse GM-CSF was kindly provided by Kirin Brewery and was purchased from PeprTech.

### Plasmid construction

Mouse TRAIL cDNA was prepared by RT-PCR amplification from total RNA of mouse spleen with PCR primers 5'-AACCTCTAGACCGC CGCCACCATGCCTTCCTCAGGGGCCCTGAA-3' and 5'-AAAGGGA TATCTTTACTGGTCATTTAGTT-3'. The design of these primers results in cloning of TRAIL cDNA downstream of the Kozak sequence (20). The PCR products were subcloned into a pGEM-T-Easy vector (Promega), and cDNA inserts were confirmed by sequencing analysis. cDNA for mouse PD-L1 was kindly provided by Drs. T. Okazaki and T. Honjo (Department of Medical Chemistry, Kyoto University, Kyoto, Japan) (7). The cDNA fragments for TRAIL and PD-L1 were cloned into pCAG-INEO, a mammalian expression vector driven by a CAG promoter and containing the internal ribosomal entry site (IRES)-neomycin resistance gene cassette, to generate pCAG-TRAIL-INEO or pCAG-PDL1-INEO. To generate a MOG peptide presenting vector, double-stranded oligo DNA encoding the MOG p35–55 epitope, 5'-CCGGTGATGGAAGTTGGTTGGTATCGTT CTCCATTCTCTCGTGTGTTTCATCTTTATCGTAACGGTAAG CTGCCCATGGGAGCT-3', was inserted into the previously reported human Ii-based epitope-presenting vector, pCI30 (2). The coding region of this construct was transferred to pCAG-IPuro, an expression vector containing the CAG promoter and IRES-puromycin *N*-acetyltransferase gene cassette, to generate pCAG-MOG-IPuro. pCI-PCC is a pigeon cytochrome *c* (PCC) epitope-presenting vector derived from pCI30 (2).

### Transfection of ES cells and differentiation of DC from ES cells

Transfection of ES cells and induction of differentiation of ES cells into DC were done as described (2, 20), with some minor modification as follows. The differentiating cells were transferred from OP9 to bacteriological petri dishes without feeder cells on day 10, and cultured in RPMI 1640 medium supplemented with 12% FCS, GM-CSF (500 U/ml), and 2-ME. The floating or loosely adherent cells were recovered from dishes by pipetting on days 17–19 and used for experiments.

### RT-PCR to detect transgene products

Total cellular RNA was extracted using a SV Total RNA Isolation kit (Promega). All RNA samples were treated with RNase-free DNase I before reverse transcription to eliminate any contaminating genomic DNA. RT-PCR was done as described (20). The relative quantity of cDNA in each sample was first normalized by PCR for GAPDH. The primer sequences were as follows: *hCD74* (II), 5'-CTGACTGACCGCGTTACTCCCACA-3' and 5'-TTCAGGGGGTTCAGCATTCTGGAGC-3'; *TRAIL*, 5'-CTGACTGAC CGCGTTACTCCCACA-3' and 5'-GAAATGGTGTCTGAAAGGTTCC-3'; *PD-L1*, 5'-CTGACTGACCGCGTTACTCCCACA-3' and 5'-GCTTGTAG TCCGCACCAACCGTAG-3'; and *GAPDH*, 5'-GGAAAGCTGTG GCGTGATG-3' and 5'-CTGTTGCTGTAGCCGTATTC-3'. The sense-strand primer used for detection of transgene-derived mRNA was corresponding to the 5' untranslated region included in the vector DNA. PCR products were visualized by ethidium bromide staining after separation over a 2% agarose gel. In one experiment, the level of expression of mRNA for *TGF-β* was detected by RT-PCR. The primer sequences were 5'-ACCATGCCAACTTCTGTCTG-3' and 5'-CGGGTTGTGTTGGT TGTA-3'.

### Flow-cytometric analysis

Staining of cells and analysis on a flow cytometer (FACScan; BD Biosciences) was done as described (2). Abs and reagent used for staining were as follows: anti-I-A<sup>b</sup> (clone 3JF; mouse IgG2a), R-PE-conjugated-anti-mouse CD11c (clone N148; hamster IgG; Chemicon), R-PE-conjugated anti-mouse CD86 (clone RMMP-2; rat IgG2a; Caltag), FITC-conjugated anti-human CD74 (clone M-B741; mouse IgG2a; BD Pharmingen), FITC-conjugated goat anti-mouse Ig (BD Pharmingen), mouse IgG2a control (clone G155-178; BD Pharmingen), FITC-conjugated mouse IgG2a control (clone G155-178; BD Pharmingen), R-PE-conjugated hamster IgG control (Immunotech), R-PE-conjugated rat IgG2a control (clone LO-DNP-16; Caltag), biotinylated anti-mouse TRAIL (clone N2B2; rat IgG2a; eBioscience), anti-mouse PD-L1 (clone MIH5; rat IgG2a; eBioscience), rat IgG2a (Caltag), biotinylated rat IgG2a (eBioscience), FITC-conjugated anti-rat Ig (BD Pharmingen), and PE conjugated-streptavidin (Molecular Probes; Invitrogen Life Technologies). In some experiments, the DC fraction was gated by forward and side scatters. For detection of apoptosis of splenic CD4<sup>+</sup> T cell, Annexin V<sup>FITC</sup> apoptosis detection kits (BioVision) were used. In brief, spleen cells isolated from mice treated with ES-DC were incubated with FITC-conjugated annexin V and R-PE-conjugated anti-mouse CD4 mAb (clone L3T4; BD Pharmingen), and subsequently analyzed by flow cytometry.

### Cytotoxicity assay and proliferation assay of T cells stimulated with anti-CD3 mAb

Standard <sup>51</sup>Cr release assay was done as described (4). For proliferation assay of T cells stimulated with anti-CD3 mAb, splenic mononuclear cells were prepared from unprimed CBF<sub>1</sub> mice, and T cells were purified using nylon wool columns. X-ray-irradiated (35 Gy) ES-DC (2 × 10<sup>6</sup>) and the T cells (1 × 10<sup>5</sup>) were seeded into wells of 96-well flat-bottom culture plates pre-coated with anti-CD3 mAb (145-2C11; eBioscience) and cultured for 4 days. [<sup>3</sup>H]Thymidine (6.7 Ci/mmol) was added to the culture (1 μCi/well) in the last 16 h. At the end of culture, cells were harvested onto glass fiber filters (Wallac), and the incorporation of [<sup>3</sup>H]thymidine was measured using scintillation counting. For blocking experiments, anti-TRAIL (clone N2B2) or anti-PD-L1 (clone MIH5) blocking mAb (5 μg/ml) was added to the culture.

### Analysis of presentation of MOG epitope by genetically modified ES-DC

MOG epitope-reactive T cells were prepared from inguinal lymph nodes of mice immunized according to protocol for EAE induction described below, using nylon wool columns. X-ray-irradiated (35 Gy) ES-DC as stimulator cells (2 × 10<sup>6</sup>) were cocultured with the MOG-reactive T cells (1.5–2 × 10<sup>5</sup>) in wells of 96-well culture plates for 3 days. Proliferation of T cells in

the last 12 h of the culture was quantified based on [<sup>3</sup>H]thymidine uptake, as described above.

#### Induction of EAE and treatment with ES-DC

For EAE induction by synthetic peptides or purified protein, 6- to 8-wk-old female CBF<sub>1</sub> mice were immunized by giving a s.c. injection at the base of the tail with a 0.2-ml IFA/PBS solution containing 600 µg of MOG p35–55 peptide and 400 µg of *Mycobacterium tuberculosis* H37Ra (Difco Laboratories) on day 0. In addition, 500 ng of purified *Bordetella pertussis* toxin (Calbiochem) were injected i.p. on days 0 and 2. For EAE induction by ES-DC presenting MOG peptide, ES-DC were injected at the base of the tail of mice ( $5 \times 10^5$  cells/mouse) at day 0, and the mice were given i.p. 500 ng of *B. pertussis* toxin in 0.2 ml of PBS on days 0 and 2. For prevention of EAE, mice were injected i.p. with ES-DC ( $1 \times 10^6$  cells/mouse/injection) on days -8, -5, and -2 (preimmunization treatment), or on days 5, 9, and 13 (postimmunization treatment). The mice were observed over a period of 42 days for clinical signs, and scores were assigned based on the following scale: 0, normal; 1, weakness of the tail and/or paralysis of the distal half of the tail; 2, loss of tail tonicity and abnormal gait; 3, partial hindlimb paralysis; 4, complete hindlimb paralysis; 5, forelimb paralysis or moribundity; 6, death.

#### Immunohistochemical analysis

Freshly excised spinal cords were immediately frozen and embedded in Tissue-Tek OCT compound (Sakura Finetechnical). Immunohistochemical staining of CD4, CD8, and Mac-1 was done, as described (20), but with some modification. In brief, serial 7-µm sections were made using cryostat and underwent immunohistochemical staining with mAbs specific to CD4 (clone L3T4; BD Pharmingen), CD8 (clone Ly-2; BD Pharmingen), or Mac-1 (clone M170; eBioscience), and N-Histofine Simple Stain Mouse MAX PO (Nichirei). Frozen sections of spleen were subjected to TUNEL staining by using ApopTag Fluorescein In Situ Apoptosis Detection kits (Serologicals). In brief, sections were incubated with digoxigenin-conjugated nucleotides and TdT, and subsequently with peroxidase-conjugated anti-digoxigenin Ab. The staining signals were developed using diaminobenzidine.

#### Analysis of T cell response to MOG or keyhole limpet hemocyanin (KLH)

Immunization of mice and restimulation of draining lymph node cells *in vitro* were done as described (26), but with some modification. In brief, ES-DC-treated and control mice were immunized at the base of the tail with MOG peptide, according to protocol for EAE induction, or 50 µg of KLH protein (Sigma-Aldrich) emulsified in CFA. After indicated days, inguinal lymph node cells and spleen cells were isolated and cultured ( $5 \times 10^5$  cells/well) in the presence of MOG peptide (0, 8, 2.5, or 80 µg/ml) or KLH (16, 50, or 160 µg/ml) in 10% horse serum/RPMI 1640/2-ME or 2% mouse serum/DMEM/2-ME/insulin-transferrin-selenium-X (Invitrogen Life Technologies), and the proliferative response was quantified based on [<sup>3</sup>H]thymidine uptake, as described above. In addition, when mice were immunized with ES-DC expressing MOG peptide for EAE induction, spleen cells were isolated at day 14, and cultured ( $5 \times 10^5$  cells/well) in the presence of MOG peptide in 10% horse serum/RPMI 1640/2-ME, and the

proliferative response was quantified based on [<sup>3</sup>H]thymidine uptake, as described above. To analyze production of cytokines of spleen cells isolated from mice treated with ES-DC, isolated spleen cells were stimulated with 10 µM MOG peptide or irrelevant OVA peptide *in vitro*. After 72 or 96 h, cell supernatants were harvested and measured for cytokine content using ELISA kits (eBioscience) for IL-4, IL-10, and IFN-γ.

#### Statistical analysis

Two-tailed Student's *t* test was used to determine the statistical significance of differences. A value of *p* < 0.05 was considered significant.

## Results

#### Induction of EAE in CBF<sub>1</sub> mice

To date, we found no study that EAE had been induced in CBF<sub>1</sub> mice. Therefore, before the study on therapeutic intervention, it was necessary to set up an experimental condition under which we could reproducibly induce EAE in CBF<sub>1</sub> mice. We compared several induction protocols using protein or peptide Ag of MOG, MBP, and PLP. As a result, we found that, when mice were s.c. injected at the base of the tail with a 0.2-ml IFA/PBS solution containing 600 µg of MOG p35–55 and 400 µg of *M. tuberculosis* accompanying an i.p. injection of 500 ng of purified *B. pertussis* toxin on days 0 and 2, EAE is reproducibly induced in CBF<sub>1</sub> mice with an average peak clinical score of 3.3 (Table I). We decided to use this protocol in the following experiments. In addition, inoculation of MBP p35–47, MBP whole protein, or PLP p190–209 together with *M. tuberculosis* and *B. pertussis* toxin also induced EAE in CBF<sub>1</sub> mice with a peak clinical score ranging between 2 and 3 (Table I).


#### Genetic modification of ES-DC to express MOG peptide along with TRAIL or PD-L1

At the first step in the generation of ES-DC presenting MOG peptide and simultaneously expressing TRAIL or PD-L1, TT2 ES cells were transfected with an expression vector for TRAIL (pCAG-TRAIL-Neo) or PD-L1 (pCAG-PDL1-Neo), as shown in Fig. 1A. Then, ES cell clones introduced with either of the expression vectors and parental TT2 ES cells were transfected with the MOG peptide expression vector, pCAG-MOG-IPuro (Fig. 1B). In this vector, a cDNA for human Ii was mutated to contain an oligo DNA encoding MOG p35–55 epitope in the CLIP region (1, 2, 27, 28). Resultant single- or double-transfectant ES cell clones were subjected to differentiation to ES-DC. ES-DC expressing MOG peptide, MOG peptide plus TRAIL, and MOG peptide plus PD-L1 were designated as ES-DC-MOG, ES-DC-TRAIL/MOG, and ES-DC-PDL1/MOG, respectively. The expression of mutant human Ii

Table I. EAE induction in CBF<sub>1</sub> mice<sup>a</sup>

Expt.	Ag	Ag Dose (µg)	Disease Incidence	Day of Onset	Mean Peak Clinical Score
1	MOG p35–55	200 × 2 <sup>b</sup>	1/2	9.0 ± 0	1.5 ± 0
2		400	2/2	11.0 ± 0	4.0 ± 0
3		600	44/44	10.2 ± 1.3	3.3 ± 0.5
4		800	2/2	8.0 ± 0	3.0 ± 0
5	MBP p35–47	200 × 2 <sup>b</sup>	0/2		
6		600	3/8	5.5 ± 1.3	3.0 ± 0
7	MBP protein	200 × 2 <sup>b</sup>	0/2		
8		600	6/6	9.7 ± 1.8	3.0 ± 0
9	PLP p190–209	200 × 2 <sup>b</sup>	0/2		
10		600	2/2	5.0 ± 0	2.0 ± 0

<sup>a</sup> Data are combined from a total of 21 experiments. EAE was induced by s.c. injection at the tail base of a 0.2-ml IFA/PBS solution containing 400 µg of *M. tuberculosis* and indicated peptide or MBP protein once (on day 0) or <sup>b</sup> twice (on days 0 and 7), together with i.p. injections of 500 ng of purified *B. pertussis* toxin on days 0 and 2.




**FIGURE 1.** Genetic modification of ES-DC to express TRAIL, PD-L1, and Ii-MOG. *A*, The structures of pCAG-TRAIL-I-Neo and pCAG-PDL1-I-Neo, the expression vectors for TRAIL and PD-L1, and PCR primers for RT-PCR to detect transgene products are shown. Primer pairs (arrows) were designed to span the intron (917 bp) in the CAG promoter sequence to distinguish PCR products of mRNA origin (421 and 604 bp, respectively) from genome-integrated vector DNA origin. Hatched boxes indicate 5'-untranslated region of the rabbit  $\beta$ -actin gene included in the CAG promoter. The vectors are driven by CAG promoter (pCAG), and cDNA for TRAIL or PD-L1 are followed by the IRES-neomycin-resistance gene (Neo<sup>R</sup>)-polyadenylation signal sequence (pA). *B*, The structure of pCAG-MOG-IPuro, the expression vector for mutant human Ii bearing MOG peptide at the CLIP region, are shown as in *A*. Primer pairs (arrows) were designed to generate PCR product of 556 bp originating from transgene-derived mRNA for CAG-MOG. *C*, RT-PCR analysis detected expression of transgene-derived mutant human Ii containing the MOG peptide (Ii-MOG), TRAIL, PD-L1, and GAPDH (control) mRNA in transfectant ES-DC.

containing the MOG peptide, TRAIL, and PD-L1 in ES-DC was confirmed by RT-PCR (Fig. 1C) and flow-cytometric analysis (Fig. 2). The mutant human Ii containing the MOG peptide was detected by intracellular staining with anti-human CD74 (Ii) mAb (Fig. 2).

ES-DC of similar morphology were generated from any of the transfectant ES cells. As shown in Fig. 2, no significant difference was observed in the level of surface expression of CD86, I-A<sup>b</sup>, or CD11c among ES-DC derived from parental TT2 ES cells, ES-DC-MOG, ES-DC-TRAIL/MOG, and ES-DC-PDL1/MOG. Thus, forced expression of TRAIL, PD-L1, or mutant human Ii has little influence on the differentiation of ES-DC.

*Functional expression of transgene-derived TRAIL and PD-L1 in ES-DC*

The functional activity of TRAIL expressed in ES-DC was analyzed according to the cytotoxicity against TRAIL-sensitive L929 cells. As shown in Fig. 3A, ES-DC-TRAIL showed manifest killing activity against L929. In contrast, neither ES-DC (TT2) (parental TT2-derived) nor ES-DC-OVA (OVA-transfected TT2-de-



**FIGURE 2.** Surface phenotype of genetically modified ES-DC. Expression of cell surface CD86, I-A<sup>b</sup>, CD11c, TRAIL, and PD-L1 on transfectant ES-DCs was analyzed by flow-cytometric analysis. Expression of mutant human Ii (hCD74) bearing MOG peptide was examined using intracellular staining. Staining patterns with specific Abs (thick line) and isotype-matched control (thin line) are shown.


rived ES-DC) did so. In addition, ES-DC-TRAIL inhibited the proliferation of splenic T cells stimulated with plate-coated anti-CD3 mAb (Fig. 3B). PD-L1 expressed on ES-DC also inhibited proliferation of splenic T cells stimulated with anti-CD3 mAb. Inhibition of anti-CD3-induced proliferation of T cells by the TRAIL and PD-L1 was abrogated by addition with anti-TRAIL and anti-PD-L1 blocking mAb, respectively (Fig. 3B), but not by isotype-matched control mAb (data not shown). These results indicate that transgene-derived TRAIL and PD-L1 expressed in ES-DC functioned to suppress response of T cells stimulated via TCR/CD3 complexes.

*Stimulation of MOG-reactive T cells by ES-DC genetically engineered to express MOG peptide*

Presentation of MOG peptide in the context of MHC class II molecules by ES-DC-MOG was investigated in vitro. MOG peptide-reactive T cells were prepared from inguinal lymph nodes of mice, which developed EAE by immunization with MOG p35-55, CFA, and *B. pertussis* toxin. Proliferative response of the MOG-reactive T cells upon coculture with transfectant ES-DC was analyzed. As shown in Fig. 4A, ES-DC-MOG stimulated the MOG-reactive T cells to induce proliferation. In contrast, ES-DC carrying Ii-based PCC peptide expression vector (ES-DC-PCC) (2), as a control, did not do so. No proliferative response was observed when naive splenic T cells isolated from syngeneic mice were cocultured with ES-DC-MOG under the same condition (data not shown). These results indicate that the epitope-presenting vector introduced into ES-DC functioned to present the MOG peptide in the context of MHC class II molecules to stimulate MOG-specific CD4<sup>+</sup> T cells.

It has been reported that transfer of bone marrow-derived DC preloaded with MOG peptide caused development of EAE in naive mice (29, 30). We presumed that, if ES-DC-MOG could encounter with MOG-specific T cells and stimulate the T cells with MOG peptide in vivo, EAE would be developed. We injected ES-DC-MOG or ES-DC-PCC, as a control, at the base of the tail of naive mice and also gave i.p. 500 ng of *B. pertussis* toxin on the same day and 2 days later. In the results, EAE was developed in the mice transferred with ES-DC-MOG but not those transferred with ES-DC-PCC (Fig. 4B).

We examined whether MOG-specific T cells were activated in vivo by injection with ES-DC-MOG. Fourteen days after the injection of ES-DC and *B. pertussis* toxin, spleen cells were isolated




**FIGURE 3.** Expression of functional TRAIL or PD-L1 in ES-DC transfectants. *A*, The activity of TRAIL expressed in ES-DC was analyzed based on cytotoxicity against L929 cell. <sup>51</sup>Cr-labeled target cells ( $5 \times 10^3$  L929 cells) were incubated with ES-DC (TT2), ES-DC-OVA, or ES-DC-TRAIL as effector cells at the indicated E:T ratio for 12 h, and after the incubation, cytolysis of target cells was quantified by measuring radioactivity in the supernatants. Results are expressed as mean specific lysis of triplicate assays, and SDs of triplicates were <4%. *B*, Irradiated ES-DC (TT2), ES-DC-TRAIL, and ES-DC-PDL1 ( $2 \times 10^4$ /well) were cocultured with  $1 \times 10^5$  syngeneic CBF<sub>1</sub> splenic T cells in the presence (□) or absence (■) of blocking Ab (anti-TRAIL mAb or anti-PD-L1 mAb, 5  $\mu$ g/ml) for 4 days in 96-well flat-bottom culture plates precoated with anti-CD3 mAb. Proliferation of T cells was quantified by measuring [<sup>3</sup>H]thymidine incorporation. The asterisks indicate that the differences in responses are statistically significant between two values indicated by lines (\*,  $p < 0.01$ ; \*\*,  $p < 0.05$ ). The data are each representative of three independent and reproducible experiments with similar results.

from the mice and cultured in the presence of MOG peptide. As shown in Fig. 4C, the spleen cells isolated from mice injected with ES-DC-MOG showed proliferative response to MOG peptide. In contrast, those isolated from mice injected with ES-DC-PCC did not do so. These results indicate that in vivo transferred ES-DC-MOG together with adjuvant effect of *B. pertussis* toxin stimulated MOG-specific T cells to develop EAE.

#### Protection from MOG-induced EAE by treatment with ES-DC expressing MOG peptide along with TRAIL or PD-L1

We examined whether TRAIL and PD-L1 expressed by ES-DC together with MOG peptide had an effect to down-modulate MOG-specific T cell responses in vitro. MOG-reactive T cells prepared as described above were cocultured with ES-DC-MOG, ES-DC-TRAIL/MOG, or ES-DC-PDL1/MOG. As shown in Fig. 5, proliferative response of the MOG-reactive T cells cocultured with ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG was significantly lower than those cocultured with ES-DC-MOG, even though the three types of ES-DC expressed an almost equal level of MOG-II (Fig. 2). These results indicate down-modulation of the response of




**FIGURE 4.** Presentation of MOG epitope by ES-DC introduced with Ii-based MOG epitope-presenting vector. *A*, T cells ( $1.5 \times 10^5$ ) isolated from inguinal lymph nodes of CBF<sub>1</sub> mice immunized according to the protocol for EAE induction were cocultured with one of two independent clones ( $2 \times 10^4$ ) of ES-DC-MOG or a clone of ES-DC-PCC, presenting PCC epitope, for 3 days. Proliferative response of T cells was quantified by [<sup>3</sup>H]thymidine uptake in the last 12 h of the culture. *B*, CBF<sub>1</sub> mice (three mice per group) were injected s.c. with ES-DC-MOG or ES-DC-PCC ( $5 \times 10^5$ ) on day 0, together with i.p. injection of 500 ng of purified *B. pertussis* toxin on days 0 and 2, and the severity of induced EAE was evaluated. The disease incidence, mean day of onset  $\pm$  SD, and mean peak clinical score  $\pm$  SD of mice injected with ES-DC-MOG were 100%,  $11.3 \pm 1.7$ , and  $2.7 \pm 0.4$ , respectively. *C*, Spleen cells were isolated on day 14 from mice treated as in *B*, and whole spleen cells ( $5 \times 10^7$ /well) were cultured in the presence of 1  $\mu$ g/ml MOG peptide for 3 days. Proliferative response was quantified as in *A*. Data were indicated as  $\Delta$ cpm (value in the presence of peptide – value in the absence of peptide (< $4.6 \times 10^3$  cpm)), and SDs of triplicates were <9% of mean value. The asterisks indicate that the differences in responses are statistically significant compared with ES-DC-PCC (\*,  $p < 0.01$ ; \*\*,  $p < 0.05$ ). The data are each representative of three independent and reproducible experiments with similar results.

MOG-reactive T cells in vitro by TRAIL and PD-L1 coexpressed together with MOG peptide on ES-DC.

We tested whether or not development of EAE would be prevented by pretreatment of mice with genetically modified ES-DC. Mice were i.p. injected with ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG at days -8, -5, and -2 ( $1 \times 10^6$  cells/mouse/injection), and sequentially immunized with MOG peptide plus adjuvants at days 0 and 2 according to the protocol described in Fig. 6A. As shown in Fig. 6B and Table II, EAE was almost





**FIGURE 5.** Decreased proliferative response to MOG peptide of MOG-reactive T cells cocultured with ES-DC expressing MOG plus TRAIL or MOG plus PD-L1. T cells ( $2 \times 10^5$ ) isolated from inguinal lymph nodes of CBF<sub>1</sub> mice immunized according to the protocol for EAE induction were cocultured with irradiated ES-DC-MOG, TRAIL/MOG, or PDL1/MOG ( $2 \times 10^6$ ) for 3 days, as in Fig. 4A. The asterisks indicate that the differences in responses are statistically significant ( $p < 0.01$ ) compared with ES-DC-MOG. The data are each representative of three independent and reproducible experiments with similar results.


completely prevented by pretreatment with either of these genetically modified ES-DC. In contrast, pretreatment with ES-DC-MOG, ES-DC-TRAIL/OVA (as irrelevant Ag), or ES-DC-PDL1/OVA had no effect (Fig. 6C and Table II). Thus, the prevention depended on both the presentation of the MOG peptide and the expression of TRAIL or PD-L1 by ES-DC. If  $2 \times 10^6$  of ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG was given as a one-injection administration, EAE was similarly prevented (data not shown). However, if  $5 \times 10^5$  of ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG was used for one injection, the disease severity was not reduced (data not shown). Thus,  $\sim 1 \times 10^6$  of genetically modified ES-DC as one-injection dose is apparently necessary for the prevention of EAE under this experimental condition.

We asked whether TRAIL or PD-L1 should be coexpressed by the same ES-DC as one presenting MOG peptide for their capacity to protect mice from EAE. As shown in Fig. 6D and Table II, coinjection of ES-DC-MOG together with ES-DC-TRAIL or ES-DC-PDL1 did not reduce the severity of EAE. Thus, coexpression of TRAIL or PD-L1 with MOG peptide by ES-DC is necessary for the protection from EAE. These results emphasize the advantage of the technology of ES cell-mediated genetic modification of DC, by which one can generate clonal transfectant DC carrying multiple expression vectors.

Next, we tested whether or not treatment with ES-DC after immunization with MOG would achieve some preventive effect on EAE. As shown in Fig. 7A, mice were immunized according to the protocol for EAE induction and, after that, injected with ES-DC on days 5, 9, and 13 ( $1 \times 10^6$  cells/mouse/injection). Even in this postimmunization treatment, injection of ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG reduced severity of the disease, but ES-DC-MOG did not do so (Fig. 7B and Table II).

#### Decreased T cell response to MOG in mice treated with ES-DC-TRAIL/MOG or -PDL1/MOG

We examined whether treatment with ES-DC-TRAIL/MOG or -PDL1/MOG would reduce the activation of MOG-specific T cells. Forty-two days after the immunization according to the protocol for EAE induction (Fig. 6A), we isolated inguinal lymph node cells and analyzed their proliferative response upon restimulation *in vitro* with MOG peptide. As shown in Fig. 8A, the magnitude of proliferation of lymph node cells isolated from mice treated with ES-DC-TRAIL/MOG or -PDL1/MOG was not increased in response to MOG peptide. In contrast, that of lymph node cells from ES-DC-MOG-treated or untreated mice was increased with statistical significance. In the presence of 25  $\mu$ g/ml MOG peptide, stimulation index (count in the presence of MOG peptide/count in the



**FIGURE 6.** Prevention of MOG-induced EAE by pretreatment of mice with ES-DC expressing MOG plus TRAIL or MOG plus PD-L1. **A**, The schedule for pretreatment and induction of EAE is shown. CBF<sub>1</sub> mice (three to five mice per group) were i.p. injected with ES-DC ( $1 \times 10^6$  cells/injection/mouse) on days -8, -5, and -2. EAE was induced by s.c. injection of MOG peptide plus *M. tuberculosis* H37Ra emulsified in IFA on day 0, and i.p. injection of *B. pertussis* toxin on days 0 and 2. **B-D**, Disease severity of mice treated with ES-DC-TRAIL/MOG, ES-DC-PDL1/MOG, or RPMI 1640 medium (control) (**B**), ES-DC-MOG, ES-DC-TRAIL/OVA, ES-DC-PDL1/OVA, or RPMI 1640 medium (control) (**C**), coinjection with ES-DC-MOG plus ES-DC-TRAIL, ES-DC-MOG plus ES-DC-PDL1, or RPMI 1640 medium (control) (**D**) is shown. The data are each representative of at least two independent and reproducible experiments, and data of all experiments are summarized in Table II.

absence of Ag) for that of untreated, ES-DC-MOG, -TRAIL/MOG, and -PDL1/MOG-treated mice were 2.8, 2.4, 1.3, and 1.0, respectively. These results suggest that treatment with ES-DC-TRAIL/MOG or -PDL1/MOG inhibited the activation of MOG-specific T cells or reduced their number in mice immunized with MOG peptide and adjuvants.

Next, we examined whether or not treatment with ES-DC would affect immune responses to an irrelevant exogenous Ag. We treated mice with ES-DC-MOG, -TRAIL/MOG, -PDL1/MOG, or RPMI 1640 medium (control) using the same schedule described above, and subsequently immunized the mice with KLH/CFA. Eleven days after the immunization, we isolated inguinal lymph

Table II. Suppression of EAE induction in CBF<sub>1</sub> mice treated with ES-DC<sup>a</sup>

Treatment (ES-DC)	Disease Incidence	Day of Onset	Mean Peak Clinical Score
No Treatment (control)	26/26	10.5 ± 1.1	3.3 ± 0.4
Pre <sup>b</sup> - TRAIL/MOG	<b>3/10</b>	18.3 ± 2.4	<b>0.3 ± 0.4</b>
Pre- PDL1/MOG	<b>5/10</b>	13.4 ± 2.1	<b>0.8 ± 0.8</b>
Pre- MOG	8/8	10.5 ± 1.3	3.0 ± 0.3
Pre- TRAIL/OVA	6/6	10.2 ± 2.9	3.0 ± 0
Pre- PDL1/OVA	6/6	11.3 ± 0.9	3.0 ± 0
Pre- TRAIL + MOG	6/6	10.2 ± 1.2	3.2 ± 0.6
Pre- PDL1 + MOG	6/6	10.2 ± 0.6	3.3 ± 0.7
Post <sup>c</sup> - TRAIL/MOG	3/6	18.7 ± 4.4	<b>0.5 ± 0.5</b>
Post- PDL1/MOG	3/6	13.7 ± 1.1	<b>1.0 ± 1.0</b>
Post- MOG	6/6	10.8 ± 1.0	3.2 ± 0.3

<sup>a</sup> Data are combined from a total of 10 separate experiments including those shown in Figs. 6 and 7. EAE was induced by s.c. injection at the tail base of a 0.2-ml IFA/PBS solution containing 400 µg of *M. tuberculosis* and 600 µg of MOG peptide once (on day 0), together with i.p. injections of 500 ng of purified *B. pertussis* toxin on days 0 and 2. For prevention of EAE, mice were injected i.p. with ES-DC ( $1 \times 10^6$  cells/mouse/injection) <sup>b</sup>on days -8, -5, and -2 (preimmunization treatment), or <sup>c</sup>on days 5, 9, and 13 (postimmunization treatment). The incidence and the clinical score reduced by ES-DC treatment are indicated in boldface.

node cells and analyzed their proliferative response upon restimulation with KLH *in vitro*. As a result, lymph node cells of ES-DC-treated and control mice showed the same magnitude of proliferative response (Fig. 8B), thereby indicating that the treatment with such genetically modified ES-DC did not affect the immune response to irrelevant Ags.

We immunohistochemically analyzed spinal cord, the target organ of the disease, of mice subjected to EAE induction with or without treatment with ES-DC. Massive infiltration of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and Mac-1<sup>+</sup> macrophages was observed in spinal cords of untreated control mice (Fig. 9). In contrast, T cells and macrophages hardly infiltrated into the spinal cord of mice treated with ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG. The results of histological analysis are in parallel with the severity of EAE and activation state of MOG-specific T cells of each mouse.

#### Increased number of apoptotic cells in splenic CD4<sup>+</sup> T cells by treatment with ES-DC-TRAIL/MOG

With regard to the mechanism of prevention of EAE by transfectant ES-DC, we analyzed the apoptosis of CD4<sup>+</sup> T cell in spleens of mice treated with ES-DC by staining with annexin V and subsequent flow-cytometric analysis. In the results, we observed that transfer of ES-DC-TRAIL/MOG caused an increase of apoptosis of CD4<sup>+</sup> T cells in recipient mice ( $17.3 \pm 2.5\%$ ), compared with transfer of ES-DC-MOG ( $12.0 \pm 0.4\%$ ), ES-DC-PDL1/MOG ( $12.2 \pm 0.5\%$ ), or RPMI 1640 medium control ( $10.2 \pm 0.8\%$ ). In the experiments, three mice were used for each group. Increased numbers of apoptotic cells in spleen of mice transferred with ES-DC-TRAIL/MOG were also observed in histological analysis with TUNEL staining (Fig. 10). The capacity of ES-DC-TRAIL/MOG to cause apoptosis of T cells may play some role in the protection from EAE.

## Discussion

DC are the most potent APC responsible for priming of naive T cells in initiation of the immune response. Recent studies revealed that DC are also involved in the maintenance of immunological self-tolerance, promoting T cells with regulatory functions, or inducing anergy of T cells. *In vivo* transfer of Ag-loaded DC with a tolerogenic character is regarded as a promising therapeutic means





FIGURE 7. Inhibition of MOG-induced EAE by treatment with ES-DC expressing MOG plus TRAIL or MOG plus PD-L1 after immunization with MOG. A, The schedule for induction of EAE and treatment is shown. CBF<sub>1</sub> mice (three mice per group) were immunized on days 0 and 2 according to the EAE induction schedule described above, and subsequently i.p. injected with ES-DC ( $1 \times 10^6$  cells/injection/mouse) on days 5, 9, and 13. B, Disease severity of mice treated with ES-DC-TRAIL/MOG, ES-DC-PDL1/MOG, ES-DC-MOG, or RPMI 1640 medium (control) is shown. The data are each representative of two independent and reproducible experiments, and data of all experiments are summarized in Table II.

to negatively manipulate immune response in an Ag-specific manner. Various culture procedures used to generate DC with a tolerogenic character have been reported (31–36). Mouse bone marrow-derived DC generated in the presence of IL-10 and/or TGF- $\beta$  or in the low dose of GM-CSF showed immature phenotypes, a low-level expression of cell surface MHC and costimulatory molecules, and induced T cell anergy *in vitro* and tolerance to specific Ags or allogeneic transplanted organs *in vivo*. In humans, monocyte-derived immature DC loaded with antigenic peptides and transferred *in vivo* have been shown to cause the Ag-specific immune suppression (37).

Genetic modification may be a more steady and reliable way to manipulate the character of DC. Generation of tolerogenic DC by forced expression of Fas ligand, indoleamine 2,3-dioxygenase, IL-10, or CTLA4Ig by gene transfer has been also reported (38–41). In a recent study, type II collagen-loaded bone marrow-derived DC genetically engineered to express TRAIL by using an adenovirus vector ameliorated type II collagen-induced arthritis (42).

Regarding methods for gene transfer to DC, electroporation, lipofection, and virus vector-mediated transfection have been reported (38–43). However, considering clinical applications, presently established methods have several drawbacks, i.e., efficiency of gene transfer, stability of gene expression, limitation of the size and number of genes to be introduced, potential risk accompanying the use of virus vectors, and the immunogenicity of the virus vectors. For the purpose of Ag-specific negative regulation of immune responses, the antigenicity of vector systems may lead to problems. Importantly, to efficiently down-modulate T cell responses in an Ag-specific manner, it is desirable to introduce multiple expression vectors to generate stable transfectant DC, which continuously present transgene-derived Ag and simultaneously express immunosuppressive molecules.




**FIGURE 8.** Inhibition of activation of MOG-reactive T cells and no effect of activation of KLH-specific T cell by treatment of mice with ES-DC expressing MOG plus TRAIL or PD-L1. *A*, Inguinal lymph node cells ( $3 \times 10^5$ ) were isolated from CBF<sub>1</sub> mice (three mice per group) of various treatment groups at over day 42, and were stimulated *ex vivo* with irradiated and MOG peptide-pulsed syngeneic spleen cells for 3 days. Proliferative response of T cells was quantified by [<sup>3</sup>H]thymidine uptake in the last 12 h of the culture. The asterisks indicate that the differences in responses are statistically significant compared with count in the absence of Ag (\*,  $p < 0.01$ ; \*\*,  $p < 0.05$ ). The data are each representative of two independent and reproducible experiments with similar results. *B*, CBF<sub>1</sub> mice (three mice per group) were *i.p.* injected with ES-DC ( $1 \times 10^6$  cells/injection/mouse) on days -8, -5, and -2, and immunized with KLH/CFA on day 0. On day 11, inguinal lymph node cells were isolated and restimulated with the indicated concentration of KLH *in vitro*. Proliferation of T cells was quantified as described above.

Efficient genetic modification of mouse DC can be done by gene transfer to ES cells and subsequent differentiation of transfectant ES cells to ES-DC. By sequential transfection of ES cells using multiple expression vectors, transfectant ES-DC expressing multiple transgene products can readily be generated. In a recent study, we demonstrated that this methodology worked very effectively for induction of antitumor immunity, showing highly efficient stimulation of Ag-specific T cells by *in vivo* transfer of ES-DC expressing T cell-attracting chemokines along with Ag (20).


The present study demonstrates the usefulness of the genetically modified DC generated by this method for the treatment of subjects with autoimmune disease. We generated ES-DC presenting the MOG epitope in the context of MHC class II molecule and simultaneously expressing immunosuppressive molecule, TRAIL or PD-L1. By pre- or posttreatment of mice with such ES-DC, we succeeded in preventing an autoimmune disease model, EAE induced by immunization with MOG peptide (Figs. 6 and 7; Table II). Down-modulation of immune response by treatment with genetically modified ES-DC did not affect the immune response to irrelevant exogenous Ag, KLH (Fig. 8*B*). Thus, we achieved the prevention of EAE without decrease in the immune response to an irrelevant Ag.

As for the function of TRAIL, induction of apoptosis has been reported by several groups (3, 4, 42, 44). We also observed an



**FIGURE 9.** Inhibition of infiltration of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and Mac-1<sup>+</sup> macrophages into spinal cord by treatment of mice with ES-DC expressing MOG plus TRAIL or PD-L1. Mice were pretreated with ES-DC-TRAIL/MOG, PDL1/MOG, or untreated and subsequently immunized according to the protocol for EAE induction as shown in Fig. 6*A*. The cervical, thoracic, and lumbar spinal cord was isolated at day 11 and subjected to immunohistochemical analysis. CD4 (*A*, *D*, and *G*), CD8 (*B*, *E*, and *H*), and Mac-1 (*C*, *F*, and *I*) staining are shown in representative untreated control (*A–C*), ES-DC-TRAIL/MOG-treated (*D–F*), and ES-DC-PDL1/MOG-treated (*G–I*) mice. *J*, The positive cells were microscopically counted in three sections of spinal cord. Results are expressed as mean  $\pm$  SD of CD4<sup>+</sup>, CD8<sup>+</sup>, Mac-1<sup>+</sup> cells per 1 mm<sup>2</sup> tissue area of samples obtained from five mice. The asterisks indicate that the decreases in number of infiltrated cells are statistically significant ( $p < 0.01$ ) compared with control.

increase in apoptosis of CD4<sup>+</sup> T cells in spleens of mice treated with ES-DC-TRAIL/MOG compared with ES-DC-MOG, PDL1/MOG or RPMI 1640 medium (control), as shown in Fig. 10. The result is consistent with a recent report by Liu et al. (42). They introduced the TRAIL gene into bone marrow-derived DC by adenovirus vector and injected the TRAIL transfectant DC into mice for prevention of collagen-induced arthritis, and also observed an increased number of apoptotic T cells in the injected mice. The



**FIGURE 10.** Induction of apoptosis of spleen cells by treatment of mice with ES-DC expressing TRAIL along with MOG peptide. Mice were treated with the indicated ES-DC and immunized with MOG peptide, following the schedule described in Fig. 6A. On day 11, spleens were isolated from the mice, and apoptotic cells were detected by in situ TUNEL staining. Original magnification,  $\times 200$ . Sections of the mice untreated (A), treated with ES-DC-MOG (B), ES-DC-TRAIL/MOG (C), and ES-DC-PDL1/MOG (D) are shown. Similar results were observed for three mice used in each experimental group, and representative results are shown.

potential for ES-DC-TRAIL/MOG to cause apoptosis of T cells may have played some role in the protection from EAE, at least in part, in our experiments. In addition, our preliminary experiments suggest that ES-DC-TRAIL/MOG induced T cells with protective effects against EAE. In the experiments, we isolated splenic  $CD4^+$  T cells from ES-DC-TRAIL/MOG-treated mice and adoptively transferred them to naive mice. The severity of subsequently induced EAE in the recipient mice was significantly reduced by this treatment (data not shown). At present, it may be possible that both induction of apoptosis of MOG-reactive pathogenic T cells and promotion of T cells with some regulatory function contributed to prevention of EAE by ES-DC-TRAIL/MOG. However, to clarify the precise mechanism or character of the T cell with regulatory function, further investigations are necessary.

In contrast, in case of treatment with ES-DC-PDL1/MOG, neither apoptosis of T cells nor induction of transferable disease-preventing T cells was observed (data not shown). We presume induction of anergy of MOG-reactive T cells to be likely as the mechanism of disease-preventive effect of treatment with ES-DC-PDL1/MOG, based on previous literature regarding the function of PD-L1 (7, 14, 45–47).

To determine whether the profile of cytokine production was altered by treatment with ES-DC, we did ELISA to quantify IL-10, IL-4, and IFN- $\gamma$  produced by spleen cells of ES-DC-treated mice upon stimulation with MOG peptide in vitro. We observed no significant change in the amount of these cytokines produced by spleen cells from ES-DC-TRAIL/MOG-treated or ES-DC-PDL1/MOG-treated mice, compared with those from ES-DC-MOG-treated mice (data not shown). The level of expression of mRNA for TGF- $\beta$  detected by RT-PCR was also unchanged compared with control (data not shown). Thus, involvement of IL-10-producing Tr-1 cells or Th2 cells in protection from EAE by treatment with ES-DC-TRAIL/MOG or ES-DC-PDL1/MOG is unlikely, although one cannot totally rule out the possibility.

The capacity of the ES cells to differentiate to ES-DC was never impaired even after culture for at least over 4 mo. Inactivation of transcription of introduced genes due to gene silencing in ES cells can be prevented using vectors bearing the IRES-drug resistance

gene or by targeted gene introduction with an exchangeable gene-trap system (2). Thus, genetically manipulated ES cells can be used as an infinite source for DC with genetically modified properties.

Recently, we established methods for generation of DC from nonhuman primate ES cells and also for genetic modification of them (S. Senju, H. Suemori, H. Matsuyoshi, S. Hirata, Y. Uemura, Y.-Z. Chen, D. Fukuma, M. Furuya, N. Nakatsuji, and Y. Nishimura, manuscript in preparation). We hope to apply this method to human ES cells to generate genetically modified human ES-DC, although some modification might be necessary. In the future, Ag-specific immune modulation therapy by in vivo transfer of human ES-DC expressing antigenic protein along with immune-regulating molecules may well be realized, based on evidence in the current study in the mouse system. Possible applications of this technology are treatment of subjects with autoimmune and allergic diseases and also for induction of tolerance to transplanted organs, especially those generated from ES cells. Thus, the methods established in the present study may have implications as a broad medical technology.

### Acknowledgments

We thank Dr. S. Aizawa (RIKEN Center for Developmental Biology, Kobe, Japan) for TT2, Drs. N. Takakura (Kanazawa University, Kanazawa, Japan) and T. Suda (Keio University, Tokyo, Japan) for OP9, Dr. H. Niwa (RIKEN Center for Developmental Biology, Kobe, Japan) for pCAG-IPuro, Drs. T. Okazaki and T. Honjo (Kyoto University, Kyoto, Japan) for a cDNA clone for PD-L1, Tatsuko Kubo (Department of Molecular Pathology, Kumamoto University) for technical assistance, and Kirin Brewery Co., Ltd., for rGM-CSF. M. Ohara (Fukuoka, Japan) provided helpful comments on the manuscript.

### References

- Fujii, S., S. Senju, Y. Z. Chen, M. Ando, S. Matsushita, and Y. Nishimura. 1998. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. *Hum. Immunol.* 59:607.
- Senju, S., S. Hirata, H. Matsuyoshi, M. Masuda, Y. Uemura, K. Araki, K. Yamamura, and Y. Nishimura. 2003. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. *Blood* 101:3501.
- Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, and R. G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. *Immunity* 3:673.
- Kayagaki, N., N. Yamaguchi, M. Nakayama, K. Takeda, H. Akiba, H. Tsutsui, H. Okamura, K. Nakanishi, K. Okumura, and H. Yagita. 1999. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. *J. Immunol.* 163:1906.
- Lamhamedi-Cherradi, S. E., S. J. Zheng, K. A. Maguschak, J. Peschon, and Y. H. Chen. 2003. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL $^{-/-}$  mice. *Nat. Immunol.* 4:255.
- Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat. Med.* 5:1365.
- Freeman, G. J., A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J. Exp. Med.* 192:1027.
- Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity* 11:141.
- Nishimura, H., T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, A. Mizoguchi, H. Hiai, N. Minato, and T. Honjo. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. *Science* 291:319.
- Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke, and B. Hilliard. 2000. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. *J. Exp. Med.* 191:1095.
- Hilliard, B., A. Wilmen, C. Seidel, T. S. Liu, R. Goke, and Y. Chen. 2001. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. *J. Immunol.* 166:1314.
- Lunemann, J. D., S. Waiczies, S. Ehrlich, U. Wendling, B. Seeger, T. Kamradt, and F. Zipp. 2002. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. *J. Immunol.* 168:4881.
- Kayagaki, N., N. Yamaguchi, M. Abe, S. Hirose, T. Shirai, K. Okumura, and H. Yagita. 2002. Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). *Cell. Immunol.* 219:82.